DaVita HealthCare (DVA) has shown a slight increase in its stock price, closing at $164.82, which is a gain of 0.15% from the previous day. However, it underperformed compared to the broader market, with the S&P 500, Dow Jones Industrial Average, and Nasdaq Composite all experiencing higher gains.
Over the past month, DaVita's shares have increased by 0.21%, outperforming the Medical sector's decline. However, it still fell short of the S&P 500's overall gain.
DaVita is scheduled to announce its earnings on October 29, 2024. Analysts expect a decrease in earnings per share compared to the same quarter last year, but anticipate revenue growth. For the full year, earnings and revenue are projected to increase compared to the previous year.
Analysts have a favorable outlook on DaVita, with a #2 (Buy) ranking. The company's valuation metrics, such as the Forward P/E ratio and PEG ratio, suggest that it may be undervalued compared to its peers in the Medical sector. These metrics are important for investors assessing the potential for growth and profitability in DaVita.